Private Practices

A handheld, easy-to-use solution that fits seamlessly into the workflow of your clinical team.

The Challenge

Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system, resulting in preventable morbidity. Physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.

The Solution

Designed with efficiency in mind, DermaSensor ensures rapid, objective test results without compromising quality. Its user-friendly interface makes it effortlessly accessible and easy to incorporate into the busy routine of medical offices. This powerful tool enhances and streamlines physicians’ management process for suspicious skin lesions and translates to tangible value for healthcare systems.

DermaSensor’s capabilities pave the way for more informed decision-making, since the device was found to have a 96% device sensitivity for correctly referring skin cancer in a study of 1,579 lesions and 224 skin cancers. Its rapid results can help minimize healthcare provider and patient time associated with referrals, creating a ripple effect of benefits for the healthcare ecosystem. Ultimately, DermaSensor improves PCPs cancer detection and appropriate referrals to dermatology, marking a significant advancement in skin cancer care in the U.S.

Empowering Clinicians with Enhanced Precision

DermaSensor is a real-time, non-invasive skin cancer evaluation system that provides point-of-care testing for all types of skin cancer.

The Burden of Skin Cancer

In the U.S., more than 9,500 people are diagnosed with skin cancer every day. More than two people die of the disease every hour and at least one in five Americans will develop skin cancer by the age of 70.*

Source: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/

While skin cancer is highly treatable at early stages, delays in identification substantially increased risk. Effective assessment of patients with potential skin cancer in primary care settings can be challenging due to handling diverse and increasing medical concerns and having limited dermatological training. But now, physicians can use DermaSensor’s AI-powered spectroscopy technology to non-invasively evaluate cellular and subcellular characteristics of a lesion in question for skin cancer. The wireless, handheld device then provides an immediate, objective result using the FDA-cleared algorithm.

Pricing

$199/month(Up to 5 patients)

$399/month(Unlimited Users & Scans)

Discover what other practitioners are saying.

Our study indicates that DermaSensor’s ESS device has the potential to enhance the detection of skin malignancies in the primary care setting. This technology not only improved PCPs’ sensitivity for lesion referral but also significantly increased their confidence, both of which are particularly important for non-specialists

The dermatology community and I have been advocating the use of dermatoscopes for decades with primary care physicians, but with limited success given the significant and repeated training that is needed. I'm thrilled that this new automated device is now available for these physicians with training time of just a few minutes.

As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important. These studies have shown the ESS device benefits physicians, and it is also a non-invasive, easy-to-use solution for instantaneously evaluating suspicious lesions.

In primary care, we don't want to miss a chance to catch skin cancer as soon as possible, but skin lesions can be challenging to evaluate. DermaSensor is fast and easy to use and adds objectivity and confidence to these clinical decisions.

As a dermatologist that trained PCPs at One Medical for years, I think this device will be transformational for PCPs correctly managing suspicious lesions.